for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Natco Pharma Ltd.

NATP.NS

Latest Trade

577.20INR

Change

9.35(+1.65%)

Volume

186,152

Today's Range

570.50

 - 

591.90

52 Week Range

480.00

 - 

799.90

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
567.85
Open
577.60
Volume
186,152
3M AVG Volume
2.58
Today's High
591.90
Today's Low
570.50
52 Week High
799.90
52 Week Low
480.00
Shares Out (MIL)
181.89
Market Cap (MIL)
103,284.70
Forward P/E
15.83
Dividend (Yield %)
0.44

Latest Developments

More

Natco Pharma Raises Stake In OMRV Hospitals Pvt Ltd To 12.81%

India's Natco Pharma June-Qtr Consol Net Profit Falls

Natco Pharma Gets Establishment Inspection Report For Kothur Facility

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Natco Pharma Ltd.

Natco Pharma Limited is a pharmaceutical company. The Company is engaged in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). The Company's segments include active pharmaceuticals ingredient, finished dosage formulations, job works, pharmacy and others. The Company's product categories include Domestic Formulations, International Formulations, API's and Blockbusters. The Company's products include Alphalan, Bandrone, Bendit, Clokeran, Lenalid, Thioplan, Anastronat, Capnat, Fulvenat, Kabanat, Natdox-LP, Rapact, Temonat, X-Trant, Glatimer, Hepcinat, Natdac, Natzold, Tigi, Alprazolam, Chloroquine Phosphate, Lansoprazole, Letrozole, Granisetron, Rizatriptan IR, Imatinib, Salmeterol Xinafoate, Sertraline Form I, Ibandronate Sodium Monohydrate, Pantoprazole Sodium Sesquihydrate, Ondansetron Hydrochloride (Injectable Grade), Daclatasvir and Glatiramer Acetate. The Company manufactures over 20 products under contract.

Industry

Biotechnology & Drugs

Contact Info

Natco House, Road No 2, Banjara Hills

+91.40.23547532

http://www.natcopharma.co.in/

Executive Leadership

V. C. Nannapaneni

Executive Chairman of the board, Managing Director

Rajeev Nannapaneni

Executive Vice Chairman of the Board, Chief Executive Officer

S. V. V. N. Appa Rao

Chief Financial Officer, Vice President - Finance and Accounts

Linga Rao

President - Technical Affairs, Director

P. S. R. K. Prasad

Executive Vice President - Corporate Engineering Services, Additional Wholetime Director

Key Stats

1.54 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

20.7K

2018

21.8K

2019

20.9K

2020(E)

22.1K
EPS (INR)

2017

27.750

2018

39.130

2019

34.870

2020(E)

35.862
Price To Earnings (TTM)
17.25
Price To Sales (TTM)
5.04
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
15.00
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-Natco Pharma Files ANDA to U.S. FDA For Sofosbuvir Tablets

* SAYS FILED AN ABBREVIATED NEW DRUG APPLICATION FOR SOFOSBUVIR TABLETS, 400MG, WITH U.S. FDA

BRIEF-Gilead: Natco And Teva Requested FDA Permission To Make Generic Version Of Sovaldi - SEC Filing

* GILEAD SCIENCES INC SAYS IN FEBRUARY 2018, CO RECEIVED NOTICES FROM NATCO PHARMA LIMITED AND TEVA PHARMA - SEC FILING

BRIEF-Natco Pharma Says Co's Mekaguda Facility Undergoing Routine U.S. FDA Inspection

* NATCO PHARMA CLARIFIES ON NEWS ITEM ON US FDA INSPECTION AT CO'S MEKAGUDA FACILITY IN TELANGANA

BRIEF-India's Natco Pharma Dec-Qtr Consol Profit Rises

* DEC QUARTER CONSOL NET PROFIT 2.18 BILLION RUPEES VERSUS PROFIT 1.95 BILLION RUPEES YEAR AGO

BRIEF-Natco Pharma Launches Tafnat, Tenofovir Alafenamide Tablets In India

* SAYS NATCO LAUNCHES TAFNAT, TENOFOVIR ALAFENAMIDE TABLETS, FOR TREATMENT OF CHRONIC HEPATITIS B, IN INDIA Source text for Eikon: Further company coverage:

BRIEF-Natco Pharma Approved Allocation Of 10 Mln Shares At 915 Rupees/Share Upon Closure Of QIP

* NATCO PHARMA - APPROVED ALLOCATION OF 10 MILLION SHARES AT ISSUE PRICE OF 915 RUPEES PER SHARE UPON CLOSURE OF QIP Source text: http://bit.ly/2zbT0ZA Further company coverage:

BRIEF-Natco Pharma Approves QIP Floor Price Of 937.63 Rupees/Shr

* SAYS APPROVED QIP FLOOR PRICE OF 937.63 RUPEES PER SHARE Source text: http://bit.ly/2AJA9El Further company coverage:

BRIEF-India's Natco Pharma Sept-qtr consol profit up about 28 pct

* Sept quarter consol net profit 848 million rupees versus profit of 665 million rupees last year

BRIEF-Natco Pharma's marketing partner Mylan launches generic glatiramer acetate in U.S.

* Says marketing partner mylan launches generic glatiramer acetate in U.S. Market Source text - http://bit.ly/2xUtxo0 Further company coverage:

BRIEF-Natco Pharma gets shareholders' nod for re-appointing V.C. Nannapaneni as chairman, MD

* Gets shareholders' nod for re-appointment of V.C. Nannapaneni as chairman, MD Source text - http://bit.ly/2wuXVkS Further company coverage:

BRIEF-Natco Pharma gets shareholders' nod for reappointment of V C Nannapaneni as chairman, MD

* Gets shareholders' nod for reappointment of V C Nannapaneni as chairman, MD

BRIEF-Natco Pharma says co, Lupin get FDA nod for generic lanthanum carbonate chewable tablets

* Says Natco, Lupin get FDA nod for generic lanthanum carbonate chewable tablets

BRIEF-India's Natco Pharma June-qtr consol profit surges

* June quarter consol profit 940 million rupees versus profit of 477 million rupees last year

BRIEF-Natco Pharma gets final ANDA approval for azacitidine for injection

* Says Natco receives final approval for generic azacitidine for injection for USA market

BRIEF-India's Natco Pharma March-qtr consol profit after tax and NCI more than doubles

* March quarter consol profit after tax and NCI at 1.77 billion rupees

BRIEF-RBI says foreign shareholding limit in Natco Pharma hiked to 49 pct

* FIIs/FPIs can now invest from 31.50 to 49 per cent under PIS in Natco Pharma Limited Source text: http://bit.ly/2qiTUzx Further company coverage:

BRIEF-Natco Pharma launches Pomalid in India

* Says Natco launches Pomalid, first generic version of pomalidomide capsules,for treatment of a specific blood cancer, in India Source text - (http://bit.ly/2r0381s) Further company coverage:

BRIEF-Natco Pharma launches drug to treat Hepatitis C virus infection

* Says drug used for the treatment of Hepatitis C Source text: (http://bit.ly/2qfTJ90) Further company coverage:

BRIEF-Natco Pharma Dec-qtr consol profit soars

* Natco pharma ltd consensus forecast for dec quarter consol net profit was 818.4 million rupees

BRIEF-Natco Pharma gets final approval for generic bendamustine HCL powder in U.S.

* Natco receives final approval for generic bendamustine hcl powder for USA market

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up